Related Experiment Videos
Regulatory T cells and type 1 diabetes
Dirk Homann1, Matthias von Herrath
1Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, CO 80262, USA. dhomann@scripps.edu
Clinical Immunology (Orlando, Fla.)
|August 17, 2004
Summary
Regulatory T cells show promise for preventing type 1 diabetes by suppressing autoimmune responses. However, clinical application faces challenges, with in vitro expansion and autologous therapy offering future possibilities.
Area of Science:
- Immunology
- Endocrinology
- Autoimmunity
Background:
- Regulatory T cells (Tregs) are crucial for maintaining immune tolerance.
- Growing interest exists in Tregs' role in type 1 diabetes pathogenesis and prevention.
- Animal models demonstrate therapeutic induction of protective Tregs.
Purpose of the Study:
- To review mechanisms of Treg-mediated diabetes prevention.
- To identify challenges in translating Treg-based therapies to clinical settings.
- To discuss the potential of in vitro amplified autologous Treg therapy.
Main Methods:
- Review of existing literature on regulatory T cells and type 1 diabetes.
- Analysis of proposed mechanisms for Treg-mediated immune suppression.
- Evaluation of challenges in clinical translation of Treg therapies.
Main Results:
- Treg-mediated diabetes prevention involves localized activation and suppression of pathogenic T cells.
- Clinical translation is hindered by risks of self-antigen immunization and confounding variables like lymphopenia.
- In vitro amplification and autologous Treg therapy show potential for future clinical use.
Conclusions:
- Regulatory T cells offer a promising therapeutic avenue for type 1 diabetes prevention.
- Significant hurdles remain in safely and effectively inducing Tregs in clinical settings.
- Advancements in in vitro Treg expansion may pave the way for autologous Treg therapy.